243 related articles for article (PubMed ID: 37655095)
1. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
[TBL] [Abstract][Full Text] [Related]
2. Combination of STING agonist with anti-vascular RGD-(KLAKLAK)
Czapla J; Drzyzga A; Ciepła J; Matuszczak S; Jarosz-Biej M; Pilny E; Cichoń T; Smolarczyk R
Cancer Immunol Immunother; 2024 Jun; 73(8):148. PubMed ID: 38832958
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
4. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity.
Xie Y; Li K; Liang J; Wang K; Gong Z; Chen X
Int J Pharm; 2024 Apr; 654():123955. PubMed ID: 38423155
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
[TBL] [Abstract][Full Text] [Related]
7. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
8. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
9. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
10. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
[TBL] [Abstract][Full Text] [Related]
11. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
[TBL] [Abstract][Full Text] [Related]
12. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
13. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
[TBL] [Abstract][Full Text] [Related]
14. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
15. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
[TBL] [Abstract][Full Text] [Related]
16. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
17. Encapsulation of STING Agonist cGAMP with Folic Acid-Conjugated Liposomes Significantly Enhances Antitumor Pharmacodynamic Effect.
Lu X; Cheng H; Xu Q; Tan X
Cancer Biother Radiopharm; 2023 Oct; 38(8):543-557. PubMed ID: 33719535
[No Abstract] [Full Text] [Related]
18. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
19. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
20. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
